A Phase 1 Trial of the Hematopoietic Growth Factor CDX-301 (rhuFlt3L) in Healthy Volunteers  by Anandasabapathy, Niroshana et al.
Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128S112with mortality rates >50% within 28 days of diagnosis. We
previously established that TNFa is involved the patho-
genesis of the disorder, with elevated levels of TNFa in
both plasma and broncho-alveolar lavage (BAL) ﬂuid of
affected patients. We now report results from a multi-
center, phase II, single arm, open label trial investigating
a soluble TNF binding protein, etanercept (Enbrel, Amgen)
for the treatment of children with IPS. Eligible patients
were <18 years, within 120 days post-SCT, with radio-
graphic evidence of diffuse pulmonary inﬁltrates, and no
evidence of active infection, sepsis syndrome, congestive
heart failure, or iatrogenic ﬂuid overload. Absence of
infection was established by a negative BAL at study entry.
In addition to standard therapy with corticosteroids (2.0
mg/kg/day), patients received etanercept (0.4 mg/kg/dose)
twice weekly x 8 doses. Steroid taper was allowed after 7
days, per investigator discretion. Response was deﬁned as
survival to day 28 plus complete discontinuation of all
supplemental oxygen support for >72 hours within the 28
day period. We enrolled 39 patients (median age 11y,
range 1-17y) between 2006 - 2011. Eleven patients were
ineligible for study treatment due to evidence of infection
by BAL, with the remaining 28 patients receiving study
therapy. At study entry, the median baseline FiO2 was 45%,
and 17 patients were mechanically ventilated. Complete
responses were seen in 20 (71%) of 28 patients, with
a median time to response 10 days (range 1-24). There
were no signiﬁcant differences in response based upon
age, gender, stem cell source, donor type, conditioning (TBI
vs non-TBI), or HLA match. Response rates were signiﬁ-
cantly higher for patients not requiring mechanical venti-
lation at study entry (100% vs 53%, p¼0.01). A non-
signiﬁcant trend towards improved response was seen in
patients treated within the initial 3 days of requiring
supplemental oxygen (83% vs 50%, p¼0.09). When
compared to historical reports, the combination of eta-
nercept plus corticosteroids was associated with strikingly
high overall survival at day 28 [89% (95% CI: 70-96)] and at
1-year [63% (95% CI: 42-79)]. Serious infectious complica-
tions during study therapy included HSV (2), CMV (2),
fungal (1), and enterocolitis (1). Grade 3-5 organ toxicities
included renal (2), GI bleed (1), hepatic (1), and CNS (2). In
conclusion, the addition of etanercept to high dose corti-
costeroids was associated with high response rates and
survival in children with IPS. Response rates were highest
in patients who did not require mechanical ventilation at
initiation of therapy. Therapy was well tolerated in this
high risk patient population. Given these promising results,
further study in children comparing this approach to
standard therapy is warranted.ORAL PRESENTATIONS
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Fms-like tyrosine kinase-3 ligand (Flt3L) uniquely binds
the Flt3 (CD135) receptor expressed on hematopoietic stem
cells (HSC), early progenitor cells, immature thymocytes, and
steady state dendritic cells and induces the proliferation,
differentiation, development and mobilization of these cells
in the bone marrow, peripheral blood, and lymphoid organs.
Given its potential as a stem cell mobilizer and immuno-
therapeutic, the safety and biologic activity of recombinant
human (rh) Flt3L were originally demonstrated in clinical
studies conducted by Immunex Inc. Development has
recently been reinitiatedwith CDX-301,which is composed of
the identical amino acid sequence and comparable biologic
activity as the product ﬁrst tested by Immunex. A Phase 1 trial
was initiated to assess the safety, pharmacokinetic, pharma-
codynamic and immunologic proﬁle of CDX-301. Using
a standard 3þ3 dose-escalating design, subjects receive daily
subcutaneous injectionof CDX-301at adose level of 1, 3,10, 25
or 75 mcg/kg x 5 days (Cohorts 1-5), 25 mcg/kg x 7 days
(Cohort 6), or 25mcg/kg x 10 days (Cohort 7), followed by 28-
day observation. 30 healthy volunteers (HV) (67% male,
median age¼ 34 years) have been enrolled. All HV in Cohorts
1-6 have completed dosing; CDX-301 administration
continues for Cohort 7. In Cohort 5, one HV with a remote
history of community acquired pneumonia was hospitalized
with community acquired pneumonia which developed on
study day 12; the event responded rapidly to antibiotic
treatment and fully recovered within 2 weeks, but was
considered a dose-limiting toxicity given the temporal asso-
ciation with CDX-301 administration. The cohort was
Abstracts / Biol Blood Marrow Transplant 19 (2013) S109eS128 S113expanded to a total of six HV. No additional infections or DLT
have been reported to date. Transient Grade 1 lymphade-
nopathy has been reported for 6 HV across multiple dose
levels. No anti-CDX-301 antibodies have been detected
through end of study day 34 in Cohorts 1-5; testing for
Cohorts 6-7 is ongoing. White blood cell count (WBC) and
monocytes increased in all HV; peak levels were observed
around Day 10 and generally returned to baseline by Day 34.
At doses above 3 mcg/kg, there was no clear dose
response; mean maximum % change from baseline for
Cohorts 3-6 ¼ 99% (range: 43-224%) for WBC and 784%
(range: 264-1400%) for monocytes. In-depth phenotypic
and/or functional analysis of hematopoietic stem cells and
dendritic cell subsets are planned. Data from this current
Phase 1 trial are consistent with previous studies showing
that rhFlt3L is well-tolerated and can safely and effectively
mobilize hematopoietic cell populations. Data from this trial
are expected to deﬁne the dosing regimen for planned trials
of CDX-301 in allogeneic hematopoietic stem cell trans-
plantation (HSCT) and immunotherapy.8
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Patients (pts) with acute myeloid leukemia (AML) who
relapse after allogeneic hematopoietic cell transplantation
(AlloHCT) have limited treatment options and their expected
survival is poor. Prognostic factors for survival in pts
relapsing after AlloHCT are unclear. We therefore analyzed
response to salvage therapy and survival. Three hundred and
forty eight pts with AML underwent AlloHCT between 2000-
2012 using umbilical cord blood (UCB, 222) or an HLA
matched related donor (RD, 126). Relapse after AlloHCT
occurred in 104 pts: 72 of 222 after UCB and 32 of 126 after
RD transplantation at a median time of 152 days (range, 77-
322). UCB and RD pts were comparable in their demographic
and disease characteristics including: cytogenetic risk,
presence of GVHD at relapse, proportion receiving immu-
nosuppressive therapy (IST) at relapse, time to relapse,
relapse site (systemic vs. isolated extramedullary), bone
marrow (BM) or percent of peripheral blood blasts at relapse,
BM donor chimerism, and concurrent infectious or GVHD-
related complications. Compared to RD, more UCB recipients
underwent reduced intensity HCT (68% vs. 41%, p¼0.01), had
active infection (25% vs. 6%, p¼0.03) or acute treatment
related complications (e.g. veno-oclusive disease, kidney
injury, cardiac arrhythmia) (33% vs. 13%, p¼0.04) at the time
of relapse. After relapse, all but 1 patient in each group
underwent IST taper with 3 recipients (2 UCB and 1 RD)achieving a complete remission (CR). In UCB and RD recipi-
ents, post-relapse active therapy consisted of systemic
chemotherapy in 21 and 6 pts, second AlloHCT in 9 and 2 pts,
supportive care in 30 and 6 pts and donor lymphocyte
infusions (DLI)  systemic chemotherapy in 0 and 12,
respectively (with no additional information on 18 pts
[UCB¼12, RD¼6] who were managed elsewhere at the time
of relapse). Survival at 1 year after relapse was 22% for all pts
(19% UCB vs. 28% RD, p¼0.32). Only 25% of pts with post-
relapse therapy achieved subsequent CR (21% UCB vs. 35%
RD, p¼0.16). In multivariable analysis, donor type was not an
independent predictor of post-relapse mortality (HR¼0.9;
95% CI 0.5-1.6, p¼0.72). Post-relapse mortality, however, was
higher in pts with PB blasts above the median (median¼3%;
HR¼3.9; 95% CI 2.2-6.9, p<0.01), active infection (HR¼2.0;
95% CI 1.1-3.9, p¼0.03), and history of other treatment
related complications at relapse (HR¼2.0; 95% CI 1.1-3.4,
p¼0.02). Pts receiving any type of active therapy (chemo-
therapy, DLI or second AlloHCT) at relapse (HR¼0.3; 95% CI
0.2-0.5, p<0.01) had lower mortality. Pts with AML who
relapsed after AlloHCT and were in a clinical condition
sufﬁcient to tolerate any therapeutic option can achieve CR
and enjoy prolonged survival compared to those that receive
supportive therapy. Despite that fact DLI is not generally
available to UCB recipients, salvage therapy with systemic
chemotherapy or second AlloHCT provides similar results.9
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Background: The Myelodysplastic Syndromes (MDS) and
Myeloproliferative Neoplasms (MPN) primarily affect older
patients ineligible for myeloablative allogeneic hematopoi-
etic cell transplantation (allo HCT). The preparative regimen
of Total Lymphoid Irradiation (TLI) and Anti-Thymocyte
Globulin (ATG) permits the establishment of donor hema-
topoiesis that is necessary for the graft versus malignancy
effect but is protective against acute Graft versus Host
Disease (aGVHD), presumably due to the enrichment of tol-
erogenic recipient NK-Tcells (Lowsky et al., NEJM 2005, Kohrt
et al, Blood 2009). Here we report the outcomes of patients
with MDS and MPN treated with TLI-ATG and allo HCT.
Methods and Patients: Patients received TLI (cumulative
dose1200 cGy) and ATG (7.5 mg/kg). GVHD prophylaxis
consisted of Cyclosporine A and Mycophenolate Mofetil. Of
51 consecutive patients treated between August 2004 and
December 2010, the median age was 63 years (range 50-73).
The initial diagnosis was de novoMDS (n¼24), CMML (n¼6),
MPN (n¼8), and therapy-related MDS (t-MDS, n¼13). Among
patients with de novoMDS, the IPSS-R score (Greenberg et al.,
Blood 2012) at the time of HCT was Very High or High (17%),
Intermediate (23%), Low or Very Low (53%) or unknown/
indeterminate (7%). Patients received mobilized peripheral
blood from matched related (45%), 10/10 matched unrelated
(45%), or mismatched unrelated donors (10%).
Results: The median follow up for living patients was 3.2
years (range 1.5-7). The three-year overall survival (OS), non-
relapse mortality (NRM), and event-free survival (EFS) were
42% (95% CI 28-56%), 8% (0.3-15%), and 31% (18-44%),
respectively. The cumulative incidence of aGVHD Grades II-
